A Randomized Controlled Phase III Clinical Study Comparing BL-M05D1 for Injection With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN) 18.2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-line Treatment
Latest Information Update: 13 Apr 2026
At a glance
- Drugs BL M05D1 (Primary) ; Docetaxel; Irinotecan; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 13 Apr 2026 New trial record